Division of Molecular Internal Medicine, Department of Internal Medicine II, University Hospital Würzburg, Röntgenring 11, 97070 Würzburg, Germany.
J Biol Chem. 2010 Mar 5;285(10):7394-404. doi: 10.1074/jbc.M109.037341. Epub 2009 Dec 28.
Tumor necrosis factor (TNF) elicits its biological activities by stimulation of two receptors, TNFR1 and TNFR2, both belonging to the TNF receptor superfamily. Whereas TNFR1-mediated signal transduction has been intensively studied and is understood in detail, especially with respect to activation of the classical NFkappaB pathway, cell death induction, and MAP kinase signaling, TNFR2-associated signal transduction is poorly defined. Here, we demonstrate in various tumor cell lines and primary T-cells that TNFR2, but not TNFR1, induces activation of the alternative NFkappaB pathway. In accord with earlier findings demonstrating that only membrane TNF, but not soluble TNF, properly activates TNFR2, we further show by use of TNFR1- and TNFR2-specific mutants of soluble TNF and membrane TNF that soluble ligand trimers fail to activate the alternative NFkappaB pathway. In accord with the known inhibitory role of TRAF2 in the alternative NFkappaB pathway, TNFR2-, but not TNFR1-specific TNF induced depletion of cytosolic TRAF2. Thus, we identified activation of the alternative NFkappaB pathway as a TNF signaling effect that can be specifically assigned to TNFR2 and membrane TNF.
肿瘤坏死因子(TNF)通过刺激两种受体,即 TNFR1 和 TNFR2,发挥其生物学活性,这两种受体均属于 TNF 受体超家族。尽管 TNFR1 介导的信号转导已被深入研究并得到详细了解,特别是关于经典 NFkappaB 途径的激活、细胞死亡诱导和 MAP 激酶信号转导,但 TNFR2 相关的信号转导尚未得到明确定义。在这里,我们在各种肿瘤细胞系和原代 T 细胞中证明,TNFR2 而不是 TNFR1 诱导替代 NFkappaB 途径的激活。与先前的发现一致,即只有膜 TNF,而不是可溶性 TNF,能够正确激活 TNFR2,我们进一步通过使用可溶性 TNF 和膜 TNF 的 TNFR1 和 TNFR2 特异性突变体表明,可溶性配体三聚体不能激活替代 NFkappaB 途径。与 TRAF2 在替代 NFkappaB 途径中的已知抑制作用一致,TNFR2-但不是 TNFR1-特异性 TNF 诱导细胞溶质 TRAF2 的耗竭。因此,我们确定了替代 NFkappaB 途径的激活是一种 TNF 信号转导效应,可专门分配给 TNFR2 和膜 TNF。